Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2013

View Archived Issues

Large-scale studies link new genes to obesity

Soligenix and Intrexon enter exclusive worldwide collaboration for melioidosis

Nucleocapsid assembly effector with efficacy in reducing viral cccDNA in vitro

Genmab reports phase II data for ofatumumab combined with bendamustine

Ferring Pharmaceuticals begins two phase III trials of elobixibat

Abide Therapeutics and Merck & Co. form collaboration

GSK-1322322 shows activity against Legionella pneumophila

Gilead to commence third phase III trial of fixed-dose combination tablet for HCV infection

Acceleron and Shire decide to conclude collaboration on ACE-031

RNL BIO files IND to commence phase II trial of RNL-JointStem for osteoarthritis

Pharmacodynamics of GS-9620 tested in chronic HCV patients

Takeda presents novel CENP-E inhibitor with oncolytic activity

DM-CHOC-PEN well tolerated in phase I trial

Shionogi & Co. discloses new HIV integrase inhibitors

Novel FGFR inhibitors patented by Orion Corp.

Beta Pharma synthesizes new agents for cancer

Fibrocell Science begins phase II trial of azficel-T in new indication

CSIR discloses novel agents for bacterial infections

Lundbeck prepares new PDE9 inhibitors for neurodegenerative disorders

Bristol-Myers Squibb divulges novel NS5B inhibitors

Regeneron expands ophthalmology pipeline

Pharmaco-Kinesis reports development of combinatorial nano-drug for gliomas and other cancers

Ambrx and Bristol-Myers Squibb form new collaboration for antibody-drug conjugates

FDA expands approval of efavirenz to patients as young as 3 months

Merck & Co. gains FDA approval for Liptruzet combination tablet

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...